With Additional Data Lilly Aims Broader Use For Verzenio In Post-Surgery Breast Cancer Setting

Eli Lilly And Co LLY announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio (abemaciclib) in combination with standard endocrine therapy (ET) for HR-positive, HER2-negative high-risk early breast cancer.
The new data showed Verzenio’s benefits held up across patient subgroups after longer follow-up.
Also read: Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage.
In 2020, The monarchE trial hit statistical significance after a median of 15.5 months follow-up. Verzenio’s addition to post-surgery endocrine therapy significantly cut the risk of invasive cancer recurrence or death by 25%, regardless of Ki-67 status.
Now, investigators have followed patients for a median of 42 months, coming to the second preplanned interim analysis of patient survival. Nearly all patients had already come off the two-year treatment period.
In the overall population, the Verzenio group had a 33.6% reduced risk of developing invasive disease recurrence or death over the control arm, which got endocrine therapy alone.
Adjuvant Verzenio also reduced the risk of developing the metastatic disease by 34.1%.
Price Action: LLY shares are up 0.26% at $369.25 on the last check Wednesday.

Momentum29.73

Growth99.75

Quality88.70

Value3.63

Short

Medium

Long